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In this discussion, 2 established researchers and clinical trialists debate their opposing views on the utility, benefits, and risks of the 
use of analytical interruption of antiretroviral therapy as a clinical trial end point and outcome measure in human studies seeking to 
induce remission of or eradicate human immunodeficiency virus infection.
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FOR THE TIME BEING, CAPITALIZING ON SENSITIVE 
ASSAYS MAY REMOVE THE NEED TO RISK HUMAN 
IMMUNODEFIENCY VIRUS (HIV) TRANSMISSION IN 
MANY CURE-RELATED STUDIES: DAVID MARGOLIS’ 
PERSPECTIVE
Antiretroviral therapy (ART) interruption poses risks to both 
study participants and their sex partners. It is the ultimate way 
to assess whether an intervention has achieved either human 
immunodeficiency virus (HIV) eradication or tight restriction 
of HIV replication, but thus far, no practical intervention short 
of transplantation protocols has substantially reduced the fre-
quency of latent persistent infection. Therefore, in the near fu-
ture it is unlikely that any intervention(s) will achieve a cure 
or a clinically relevant viral remission of HIV [1, 2]. Further, 
the phenomenon of “posttreatment control” has recently been 
recognized in a small minority of HIV-infected participants 
without any intervention but standard ART [3]. Therefore, 
studies aimed at achieving clinically relevant viral remission, 
defined as periods of clinical aviremia without ART that are 
measured in months to years, require large study groups with 
sham treatments or placebo arms and extensive monitoring 
and follow-up, exacerbating the burdens and risks for the study 
participant.
However, tractable assays are already available to directly or 
indirectly measure latent, persistent infection and can be used 
in intensive, single-center studies [4–7]. While such assays are 
not simple or cheap, they should be the end point of current 
cure-related studies. There is no need to interrupt ART and 
deal with the attendant risks of viral rebound for the study 
participants and their partners. Only if substantial depletion 
of persistent infection can be demonstrated in these near-term 
studies should further studies that include ART interruption as 
an end point be considered.
If the goal of interventions is to create drug-free remission 
without viral eradication, it is prudent to first ask whether 
people with immune-based viral control experience adverse 
health effects due to the need to mobilize chronic antiviral im-
mune responses [8, 9]. This concern is serious enough to war-
rant a study that compares health outcomes between those who 
initiate ART and those who do not, in a cohort with long-term 
innate control of HIV infection. Nevertheless, there may be 
some HIV-positive people who are now willing to undergo the 
risks of an analytical treatment interruption (ATI) for the sake 
of a research protocol aimed at inducing control of viremia, not 
cure. Such protocols must then deal with the challenges that 
were previously faced by therapeutic vaccine protocols: How 
much viremia during ATI will be tolerated? For how long? How 
will this be monitored? Study designs might mitigate some 
concerns by using laboratory assays and reserving ART inter-
ruption for study participants demonstrated to have gained an 
antiviral response that may lead to viral control.
Overall, it is important to be realistic about the current state of 
HIV cure science. Considering the risks of ATI to participants, 
their sex partners, and any other individuals later exposed in a 
potential chain of HIV transmission, the scientific benefits of a 
study must be substantial to justify a study that includes ATI, 
even if clinical safety parameters can be met for the individual 
participants. Given the early state of cure research and the low 
likelihood that anything tested in the near future is likely to have 
clinical benefits, research should first focus on measurements of 
progress that can be achieved without ATI. The serious risks 
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to study participants, as well as to nonparticipants, demand 
nothing less.
WITH APPROPRIATE PRECAUTIONS, ANALYTICAL 
TREATMENT INTERRUPTIONS REMAIN 
UNAVOIDABLE IN SOME CURE-RELATED STUDIES: 
STEVEN DEEKS’ PERSPECTIVE
ATIs carry risks to participants and to nonparticipants, but 
there is no substitute for them if we are to make progress toward 
a cure for HIV. Cure-related assays do not directly measure the 
relevant reservoir (eg, the replication-competent virus popu-
lation that initiates new rounds of infection). Even assays that 
probably provide reasonable, albeit unproven, quantification 
are laborious, have limited range, are difficult to apply to tissue 
specimens, and have yet to be validated. Immunologic assays 
that might predict remission are also lacking, in part because 
the correlates of posttreatment control remain unknown. Even 
if a promising virologic or immunologic assay emerged, the 
clinical trials necessary for its validation as a legitimate surro-
gate marker do not exist.
Given the lack of a valid surrogate marker for cure-related 
research, the only real option is to rely on validated surrogate 
markers of the disease, namely plasma HIV RNA levels. Since 
the goal of any curative intervention is to extend the degree of 
ART-free virus suppression, the inconvenient truth is that there 
really is no viable way to truly define how a drug works other 
than to interrupt therapy and measure the outcome.
Only heroic interventions such as stem cell transplantation 
[10] or very early ART [11, 12] have moved the dial in terms
of time to rebound, stemming either from the failure of most
interventions to affect the reservoir size (the likeliest expla-
nation) or from the insensitivity of this outcome to anything
short of a multiple-log reduction in the reservoir [13]. I agree
that, for interventions that are not expected to affect time to re-
bound and for which other outcome measures are available (eg,
virus production in the case of latency-reversing agents), ART
interruptions are unnecessary and should be avoided. However, 
in contrast to reservoir-reducing interventions (ie, those that
seek to alter the postinterruption set point), the correlates of
posttreatment control are not known, and an interruption of
ART is often necessary.
Risks to study participants from treatment interruptions 
are generally well known and easy to quantify. Truly informed 
consent is possible because most study participants have ex-
perience with both treated and untreated HIV and an instinc-
tive understanding regarding the risks of interrupting therapy. 
This contrasts with the substantial, new, and often difficult-to-
quantify risks of the many curative interventions being tested. 
When done in a well-resourced and highly monitored setting, 
many of these risks to study participants can be mitigated. Risks 
to sex partners are also known, but how to inform those part-
ners and how to reduce that risk remain to be defined.
In summary, because no biomarker for cure research exists, 
we need to turn to other outcomes. Although ATIs have many 
limitations, they are informative, and their risks for participants 
and, to some degree, for nonparticipants, can be managed 
through informed consent and careful monitoring.
RESPONSE TO STEVEN DEEKS, BY DAVID 
MARGOLIS
The statement that viral outgrowth assays have yet to be 
validated is simply wrong [5–7]. The harsh reality is that sub-
stantial depletion of persistent infection—a change that would 
register as an indisputable success in viral outgrowth assays—
has thus far only been achieved by the heroic interventions 
mentioned, such as early ART or bone marrow transplantation. 
And while in some cases even these interventions did not sub-
stantially delay rebound, at least the favorable assay metric jus-
tified the hope that there might be a delay. At the same time, 
it appears likely that, at minimum, a result of such magnitude 
would be required, to induce a very durable viral remission or 
even viral eradication. Until such an early signal of success is 
achieved, only careful, costly, demanding studies of cure-related 
interventions should be done, and they should be limited to 
small, extensively monitored cohorts.
However, if cure is not the goal of an experimental trial, and 
all that is sought is control of viremia without ART, then that is 
another matter. Individuals participated in therapeutic vaccine 
studies over a decade ago with the goal of replacing ART. These 
were never presented as studies to achieve cure or remission. In 
such studies, assays to measure the frequency of persisting viral 
infection might or might not be useful. And in such studies, 
then and now, the issue of the infectiousness of participants fol-
lowing an ATI must be dealt with.
RESPONSE TO DAVID MARGOLIS, BY 
STEVEN DEEKS
The question of whether the current assays are “validated” 
depends on definitions. The field desperately needs an assay 
that can be used as the primary end point in the emerging spec-
trum of cure-related clinical trials. For such a biomarker to be 
transformative, the field will need to prove that changes in the 
measurement predict the clinical effectiveness of the interven-
tion. A “chicken and egg” problem exists, however, in that we 
need an effective intervention to validate the capacity of a meas-
urement to predict any treatment effect.
The plasma HIV RNA assay is a classic example of an effec-
tive surrogate marker. Once it was shown that changes in HIV 
RNA predict changes in morbidity and mortality [14], drug dis-
covery and development became far easier, leading to where we 
are today, with dozens of approved drugs.
Given the experimental nature of most ongoing “probe” 
studies, using potential biomarkers such as the virus outgrowth 
assay or the next generation of DNA assays may be reasonable, 
particularly for interventions aimed at reducing the reservoir, 
but how informative they truly are is not yet known.
A carefully performed treatment interruption will always pro-
vide valuable data regarding how an intervention works. These 
studies will also provide an outcome measure to help discover 
and validate any reservoir measurement. The only compelling 
reason not to do them is safety. In this clinician’s experience, it is 
easy to explain the direct risks to the participant and the indirect 
risks to their sex partners. It is also easy to predict and manage 
any direct complications experienced by the participant if re-
sources are available to do very careful monitoring. In contrast, 
it is not easy to explain risks to and manage them in sex partners, 
because partners are often not involved in the consent process 
and may not even be aware the study is happening. Our approach 
is to provide as much education as possible to the participant and 
to refer interested partners to local services that provide preex-
posure prophylaxis and other interventions. The time may come 
when those who fund and perform these studies will need to pro-
vide preexposure prophylaxis and other services to any and all 
partners. This may require separate protocols and consent forms 
and will require significant resources. The prevention field has 
struggled with similar issues and may be able to provide guidance 
on how those doing cure research should proceed.
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